Hexamethylene bisacetamide-induced cutaneous vasculitis.
Nonthrombocytopenic purpura developed in a patient receiving hexamethylene bisacetamide, a tumor-differentiating agent in vitro that is in phase I clinical trials. Histopathological examination revealed features of leukocytoclastic vasculitis with deposition of IgA and complement in the dermal vasculature. Leukocytoclastic vasculitis, an extremely rare complication of therapy with antineoplastic agents, is reported to alert others using this compound of this association.
D000081:Acetamides / Q000009:adverse effects*; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003165:Complement System Proteins / Q000032:analysis; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D012867:Skin / Q000098:blood supply / Q000473:pathology; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology
D000081:Acetamides; D000970:Antineoplastic Agents; D007070:Immunoglobulin A; D003165:Complement System Proteins; C014026:hexamethylene bisacetamide